Personalized, predictive, preventive, participatory

"If ever there was a time to understand the need for speed in the development of new medical treatments, this year of COVID-19 has been it. It is a call to action for all of us to take a hard look at our processes and determine if we are ready for the future. So, to support rapid and sustainable development, Dassault Systèmes and the U.S. Food and Drug Administration (FDA) have extended our collaborative research agreement by 5 years, recognizing the transformative impact of modeling and simulation on public health and patient safety. This extended agreement also supports the 21st Century Cures Act, legislation introduced in 2016 to modernize clinical trials, speed the introduction of new medical technology, and give the FDA greater latitude to recruit support from scientific and technical experts to that end..." Lire la suite